Arbor Vita Corporation (AVC), a biopharmaceutical company developing both diagnostics and therapeutics, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration for its AVantage(TM) A/H5N1 Flu Test. This is a non-invasive rapid diagnostic device for the specific detection...
Arbor Vita Receives FDA Clearance Of Its AVantage(TM) A/H5N1 Flu Diagnostic - First Rapid Test For Avian Influenza In Humans
ATCC Develops And Isolates Novel Avian Flu Monoclonal Antibodies
ATCC® (American Type Culture Collection) researchers have developed a panel of novel monoclonal antibodies (mAbs) against avian influenza viruses. These antibodies could lead to a rapid diagnostic test for the infection, ATCC announced yesterday. The organization has filed a patent covering the development...
Vical Pandemic Influenza Vaccines Achieve T-Cell Responses And Cross-Clade Reactivity In Humans
Vical Incorporated (Nasdaq: VICL) announced that the company’s Vaxfectin(R)-formulated H5N1 pandemic influenza DNA vaccines induced T-cell responses against a matching strain of influenza virus and demonstrated cross-clade antibody responses against a different strain in a Phase 1 clinical trial....
A New Way To Predict Outbreaks: Replikin Peptide Concentration In H5N1 Influenza Virus Genome As A Marker For Lethal Outbreaks
WHO and CDC have stated that the predictive accuracy of their annual formulations for human influenza vaccines is “suboptimal” — often correct less than 50% of the time, especially for seniors. Perhaps in part because we are not yet accurate in our predictions of upcoming influenza...
A New Way To Predict Outbreaks: Replikin Peptide Concentration In H5N1 Influenza Virus Genome As A Marker For Lethal Outbreaks
WHO and CDC have stated that the predictive accuracy of their annual formulations for human influenza vaccines is “suboptimal” — often correct less than 50% of the time, especially for seniors. Perhaps in part because we are not yet accurate in our predictions of upcoming influenza...
Genetic Evidence For Avian Influenza Movement From Asia To North America Via Wild Birds
Wild migratory birds may be more important carriers of avian influenza viruses from continent to continent than previously thought, according to new scientific research that has important implications for highly pathogenic avian influenza virus surveillance in North America. As part of a multi-pronged...
Pandemic Research Receives $1.6M Funding Boost
Densely populated cities and increased air travel can be factors which create and spread pandemic disease. But a McMaster University researcher is working with isolated Hutterite communities to understand the transmission of pandemic diseases like influenza. Dr. Mark Loeb and his research team have received...
Inovio Biomedical’s First Proprietary DNA Vaccine Achieves 100% Protection Against Avian Flu In Pre-Clinical Testing
Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using a proprietary electroporation-based DNA delivery platform, announced recently pre-clinical results from two proprietary plasmid DNA-based universal influenza vaccine candidates using the company’s...
Sinovac Initiates Phase II Volunteer Enrollment For Split Viron Pandemic Influenza (H5N1) Vaccine
Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, announced the initiation of volunteer enrollment in its Phase II clinical trial for its split pandemic influenza vaccine. The preliminary results from this study are expected to be available in early 2009. The randomized and double-blind...
Biotech Experts Available To Discuss The Critical Role Of Vaccine Adjuvants In Treating Pandemic Bird Flu
The likelihood of an influenza pandemic caused by an avian influenza (Bird Flu) virus is an increasing concern to the World Health Organization (WHO) and others. Recent breakthroughs on promising cell-based vaccines are encouraging, but manufacturing, stockpiling and distributing enough vaccine to treat...